2020 Narcolepsy Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Narcolepsy pipeline report presents a comprehensive overview of the research and development of Narcolepsy drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: One drug in Research phase, four drugs in Pre-clinical phase, four drugs in Phase 1, five drugs in Phase 2, three drugs in Phase 3 and one drug in pre-registration phase
As of February 2020, the Narcolepsy pipeline remains robust with 19 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Narcolepsy treatment. Diverse types of targeted therapies are being explored through clinical trials including Adrenergic receptor agonists; Adrenergic uptake inhibitors; Dopamine uptake inhibitors; GABA A receptor antagonist; GABA B receptor agonists; Histamine H3 receptor antagonists; Orexin receptor type 1 agonists; Orexin receptor type 2 agonists; Prostaglandin D2 receptor antagonists; TAAR1 agonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Narcolepsy drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Narcolepsy pipeline drugs profiled in the report include- FT218 (sodium oxybate), BTD-001 (Pentylenetetrazole), pitolisant, RO5256390, mazindol, JZP-258, JZP-507, ONO-4127Na, OX1 and OX2 agonists for Narcolepsy, SLS-010, solriamfetol, SUVN-G3031, TAK-925, THN102 (flecainide and modafinil), XW-10172, XWL-008, dextroamphetamine, mazindol , reboxetine
As of February 2020, the Narcolepsy pipeline remains robust with 19 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Narcolepsy treatment. Diverse types of targeted therapies are being explored through clinical trials including Adrenergic receptor agonists; Adrenergic uptake inhibitors; Dopamine uptake inhibitors; GABA A receptor antagonist; GABA B receptor agonists; Histamine H3 receptor antagonists; Orexin receptor type 1 agonists; Orexin receptor type 2 agonists; Prostaglandin D2 receptor antagonists; TAAR1 agonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Narcolepsy drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Narcolepsy development
- Narcolepsy pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Narcolepsy pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Narcolepsy pipeline candidates included
- Business overview and snapshot of all companies involved in Narcolepsy pipeline are included
- Latest market and pipeline developments are provided in the report
Narcolepsy pipeline drugs profiled in the report include- FT218 (sodium oxybate), BTD-001 (Pentylenetetrazole), pitolisant, RO5256390, mazindol, JZP-258, JZP-507, ONO-4127Na, OX1 and OX2 agonists for Narcolepsy, SLS-010, solriamfetol, SUVN-G3031, TAK-925, THN102 (flecainide and modafinil), XW-10172, XWL-008, dextroamphetamine, mazindol , reboxetine
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Narcolepsy Condition
2.3 Narcolepsy Pipeline Snapshot, 2020
2.4 Companies investing in Narcolepsy pipeline therapeutics
2.5 Phase wise Narcolepsy Pipeline Candidates
2.6 Most Researched Mechanism of Action of Narcolepsy Pipeline Products
2.7 Route of Administration of Narcolepsy Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Avadel Pharmaceuticals Plc Overview, Contacts and ASD Pipeline Drugs
3.2 Axsome Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Balance Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Bioprojet SCR Overview, Contacts and ASD Pipeline Drugs
3.5 F. Hoffmann-La Roche Ltd Overview, Contacts and ASD Pipeline Drugs
3.6 Inexia Overview, Contacts and ASD Pipeline Drugs
3.7 Jazz Pharmaceuticals Plc Overview, Contacts and ASD Pipeline Drugs
3.8 NLS Pharma Group Overview, Contacts and ASD Pipeline Drugs
3.9 NLS Pharmaceutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.10 Ono Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.11 Seelos Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.12 SK Biopharmaceuticals Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.13 Suven Neurosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.14 Takeda Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.15 Theranexus SAS Overview, Contacts and ASD Pipeline Drugs
3.16 Vallon Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.17 XW Laboratories Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 FT218 (sodium oxybate) Drug Details
4.1.1 FT218 (sodium oxybate) Current Status
4.1.2 FT218 (sodium oxybate) Drug Overview
4.1.3 FT218 (sodium oxybate) Mechanism of Action
4.1.4 FT218 (sodium oxybate) Licensing/Collaboration Companies
4.1.5 FT218 (sodium oxybate) Clinical Trials
4.2 BTD-001 (Pentylenetetrazole) Drug Details
4.2.1 BTD-001 (Pentylenetetrazole) Current Status
4.2.2 BTD-001 (Pentylenetetrazole) Drug Overview
4.2.3 BTD-001 (Pentylenetetrazole) Mechanism of Action
4.2.4 BTD-001 (Pentylenetetrazole) Licensing/Collaboration Companies
4.2.5 BTD-001 (Pentylenetetrazole) Clinical Trials
4.3 pitolisant Drug Details
4.3.1 pitolisant Current Status
4.3.2 pitolisant Drug Overview
4.3.3 pitolisant Mechanism of Action
4.3.4 pitolisant Licensing/Collaboration Companies
4.3.5 pitolisant Clinical Trials
4.4 RO5256390 Drug Details
4.4.1 RO5256390 Current Status
4.4.2 RO5256390 Drug Overview
4.4.3 RO5256390 Mechanism of Action
4.4.4 RO5256390 Licensing/Collaboration Companies
4.4.5 RO5256390 Clinical Trials
4.5 mazindol Drug Details
4.5.1 mazindol Current Status
4.5.2 mazindol Drug Overview
4.5.3 mazindol Mechanism of Action
4.5.4 mazindol Licensing/Collaboration Companies
4.5.5 mazindol Clinical Trials
4.6 JZP-258 Drug Details
4.6.1 JZP-258 Current Status
4.6.2 JZP-258 Drug Overview
4.6.3 JZP-258 Mechanism of Action
4.6.4 JZP-258 Licensing/Collaboration Companies
4.6.5 JZP-258 Clinical Trials
4.7 JZP-507 Drug Details
4.7.1 JZP-507 Current Status
4.7.2 JZP-507 Drug Overview
4.7.3 JZP-507 Mechanism of Action
4.7.4 JZP-507 Licensing/Collaboration Companies
4.7.5 JZP-507 Clinical Trials
4.8 ONO-4127Na Drug Details
4.8.1 ONO-4127Na Current Status
4.8.2 ONO-4127Na Drug Overview
4.8.3 ONO-4127Na Mechanism of Action
4.8.4 ONO-4127Na Licensing/Collaboration Companies
4.8.5 ONO-4127Na Clinical Trials
4.9 OX1 and OX2 agonists for Narcolepsy Drug Details
4.9.1 OX1 and OX2 agonists for Narcolepsy Current Status
4.9.2 OX1 and OX2 agonists for Narcolepsy Drug Overview
4.9.3 OX1 and OX2 agonists for Narcolepsy Mechanism of Action
4.9.4 OX1 and OX2 agonists for Narcolepsy Licensing/Collaboration Companies
4.9.5 OX1 and OX2 agonists for Narcolepsy Clinical Trials
4.10 SLS-010 Drug Details
4.10.1 SLS-010 Current Status
4.10.2 SLS-010 Drug Overview
4.10.3 SLS-010 Mechanism of Action
4.10.4 SLS-010 Licensing/Collaboration Companies
4.10.5 SLS-010 Clinical Trials
4.11 solriamfetol Drug Details
4.11.1 solriamfetol Current Status
4.11.2 solriamfetol Drug Overview
4.11.3 solriamfetol Mechanism of Action
4.11.4 solriamfetol Licensing/Collaboration Companies
4.11.5 solriamfetol Clinical Trials
4.12 SUVN-G3031 Drug Details
4.12.1 SUVN-G3031 Current Status
4.12.2 SUVN-G3031 Drug Overview
4.12.3 SUVN-G3031 Mechanism of Action
4.12.4 SUVN-G3031 Licensing/Collaboration Companies
4.12.5 SUVN-G3031 Clinical Trials
4.13 TAK-925 Drug Details
4.13.1 TAK-925 Current Status
4.13.2 TAK-925 Drug Overview
4.13.3 TAK-925 Mechanism of Action
4.13.4 TAK-925 Licensing/Collaboration Companies
4.13.5 TAK-925 Clinical Trials
4.14 THN102 (flecainide and modafinil) Drug Details
4.14.1 THN102 (flecainide and modafinil) Current Status
4.14.2 THN102 (flecainide and modafinil) Drug Overview
4.14.3 THN102 (flecainide and modafinil) Mechanism of Action
4.14.4 THN102 (flecainide and modafinil) Licensing/Collaboration Companies
4.14.5 THN102 (flecainide and modafinil) Clinical Trials
4.15 XW-10172 Drug Details
4.15.1 XW-10172 Current Status
4.15.2 XW-10172 Drug Overview
4.15.3 XW-10172 Mechanism of Action
4.15.4 XW-10172 Licensing/Collaboration Companies
4.15.5 XW-10172 Clinical Trials
4.16 XWL-008 Drug Details
4.16.1 XWL-008 Current Status
4.16.2 XWL-008 Drug Overview
4.16.3 XWL-008 Mechanism of Action
4.16.4 XWL-008 Licensing/Collaboration Companies
4.16.5 XWL-008 Clinical Trials
4.17 dextroamphetamine Drug Details
4.17.1 dextroamphetamine Current Status
4.17.2 dextroamphetamine Drug Overview
4.17.3 dextroamphetamine Mechanism of Action
4.17.4 dextroamphetamine Licensing/Collaboration Companies
4.17.5 dextroamphetamine Clinical Trials
4.18 mazindol Drug Details
4.18.1 mazindol Current Status
4.18.2 mazindol Drug Overview
4.18.3 mazindol Mechanism of Action
4.18.4 mazindol Licensing/Collaboration Companies
4.18.5 mazindol Clinical Trials
4.19 reboxetine Drug Details
4.19.1 reboxetine Current Status
4.19.2 reboxetine Drug Overview
4.19.3 reboxetine Mechanism of Action
4.19.4 reboxetine Licensing/Collaboration Companies
4.19.5 reboxetine Clinical Trials
5. LATEST NARCOLEPSY PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Narcolepsy Condition
2.3 Narcolepsy Pipeline Snapshot, 2020
2.4 Companies investing in Narcolepsy pipeline therapeutics
2.5 Phase wise Narcolepsy Pipeline Candidates
2.6 Most Researched Mechanism of Action of Narcolepsy Pipeline Products
2.7 Route of Administration of Narcolepsy Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Avadel Pharmaceuticals Plc Overview, Contacts and ASD Pipeline Drugs
3.2 Axsome Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Balance Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Bioprojet SCR Overview, Contacts and ASD Pipeline Drugs
3.5 F. Hoffmann-La Roche Ltd Overview, Contacts and ASD Pipeline Drugs
3.6 Inexia Overview, Contacts and ASD Pipeline Drugs
3.7 Jazz Pharmaceuticals Plc Overview, Contacts and ASD Pipeline Drugs
3.8 NLS Pharma Group Overview, Contacts and ASD Pipeline Drugs
3.9 NLS Pharmaceutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.10 Ono Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.11 Seelos Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.12 SK Biopharmaceuticals Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.13 Suven Neurosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.14 Takeda Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.15 Theranexus SAS Overview, Contacts and ASD Pipeline Drugs
3.16 Vallon Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.17 XW Laboratories Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 FT218 (sodium oxybate) Drug Details
4.1.1 FT218 (sodium oxybate) Current Status
4.1.2 FT218 (sodium oxybate) Drug Overview
4.1.3 FT218 (sodium oxybate) Mechanism of Action
4.1.4 FT218 (sodium oxybate) Licensing/Collaboration Companies
4.1.5 FT218 (sodium oxybate) Clinical Trials
4.2 BTD-001 (Pentylenetetrazole) Drug Details
4.2.1 BTD-001 (Pentylenetetrazole) Current Status
4.2.2 BTD-001 (Pentylenetetrazole) Drug Overview
4.2.3 BTD-001 (Pentylenetetrazole) Mechanism of Action
4.2.4 BTD-001 (Pentylenetetrazole) Licensing/Collaboration Companies
4.2.5 BTD-001 (Pentylenetetrazole) Clinical Trials
4.3 pitolisant Drug Details
4.3.1 pitolisant Current Status
4.3.2 pitolisant Drug Overview
4.3.3 pitolisant Mechanism of Action
4.3.4 pitolisant Licensing/Collaboration Companies
4.3.5 pitolisant Clinical Trials
4.4 RO5256390 Drug Details
4.4.1 RO5256390 Current Status
4.4.2 RO5256390 Drug Overview
4.4.3 RO5256390 Mechanism of Action
4.4.4 RO5256390 Licensing/Collaboration Companies
4.4.5 RO5256390 Clinical Trials
4.5 mazindol Drug Details
4.5.1 mazindol Current Status
4.5.2 mazindol Drug Overview
4.5.3 mazindol Mechanism of Action
4.5.4 mazindol Licensing/Collaboration Companies
4.5.5 mazindol Clinical Trials
4.6 JZP-258 Drug Details
4.6.1 JZP-258 Current Status
4.6.2 JZP-258 Drug Overview
4.6.3 JZP-258 Mechanism of Action
4.6.4 JZP-258 Licensing/Collaboration Companies
4.6.5 JZP-258 Clinical Trials
4.7 JZP-507 Drug Details
4.7.1 JZP-507 Current Status
4.7.2 JZP-507 Drug Overview
4.7.3 JZP-507 Mechanism of Action
4.7.4 JZP-507 Licensing/Collaboration Companies
4.7.5 JZP-507 Clinical Trials
4.8 ONO-4127Na Drug Details
4.8.1 ONO-4127Na Current Status
4.8.2 ONO-4127Na Drug Overview
4.8.3 ONO-4127Na Mechanism of Action
4.8.4 ONO-4127Na Licensing/Collaboration Companies
4.8.5 ONO-4127Na Clinical Trials
4.9 OX1 and OX2 agonists for Narcolepsy Drug Details
4.9.1 OX1 and OX2 agonists for Narcolepsy Current Status
4.9.2 OX1 and OX2 agonists for Narcolepsy Drug Overview
4.9.3 OX1 and OX2 agonists for Narcolepsy Mechanism of Action
4.9.4 OX1 and OX2 agonists for Narcolepsy Licensing/Collaboration Companies
4.9.5 OX1 and OX2 agonists for Narcolepsy Clinical Trials
4.10 SLS-010 Drug Details
4.10.1 SLS-010 Current Status
4.10.2 SLS-010 Drug Overview
4.10.3 SLS-010 Mechanism of Action
4.10.4 SLS-010 Licensing/Collaboration Companies
4.10.5 SLS-010 Clinical Trials
4.11 solriamfetol Drug Details
4.11.1 solriamfetol Current Status
4.11.2 solriamfetol Drug Overview
4.11.3 solriamfetol Mechanism of Action
4.11.4 solriamfetol Licensing/Collaboration Companies
4.11.5 solriamfetol Clinical Trials
4.12 SUVN-G3031 Drug Details
4.12.1 SUVN-G3031 Current Status
4.12.2 SUVN-G3031 Drug Overview
4.12.3 SUVN-G3031 Mechanism of Action
4.12.4 SUVN-G3031 Licensing/Collaboration Companies
4.12.5 SUVN-G3031 Clinical Trials
4.13 TAK-925 Drug Details
4.13.1 TAK-925 Current Status
4.13.2 TAK-925 Drug Overview
4.13.3 TAK-925 Mechanism of Action
4.13.4 TAK-925 Licensing/Collaboration Companies
4.13.5 TAK-925 Clinical Trials
4.14 THN102 (flecainide and modafinil) Drug Details
4.14.1 THN102 (flecainide and modafinil) Current Status
4.14.2 THN102 (flecainide and modafinil) Drug Overview
4.14.3 THN102 (flecainide and modafinil) Mechanism of Action
4.14.4 THN102 (flecainide and modafinil) Licensing/Collaboration Companies
4.14.5 THN102 (flecainide and modafinil) Clinical Trials
4.15 XW-10172 Drug Details
4.15.1 XW-10172 Current Status
4.15.2 XW-10172 Drug Overview
4.15.3 XW-10172 Mechanism of Action
4.15.4 XW-10172 Licensing/Collaboration Companies
4.15.5 XW-10172 Clinical Trials
4.16 XWL-008 Drug Details
4.16.1 XWL-008 Current Status
4.16.2 XWL-008 Drug Overview
4.16.3 XWL-008 Mechanism of Action
4.16.4 XWL-008 Licensing/Collaboration Companies
4.16.5 XWL-008 Clinical Trials
4.17 dextroamphetamine Drug Details
4.17.1 dextroamphetamine Current Status
4.17.2 dextroamphetamine Drug Overview
4.17.3 dextroamphetamine Mechanism of Action
4.17.4 dextroamphetamine Licensing/Collaboration Companies
4.17.5 dextroamphetamine Clinical Trials
4.18 mazindol Drug Details
4.18.1 mazindol Current Status
4.18.2 mazindol Drug Overview
4.18.3 mazindol Mechanism of Action
4.18.4 mazindol Licensing/Collaboration Companies
4.18.5 mazindol Clinical Trials
4.19 reboxetine Drug Details
4.19.1 reboxetine Current Status
4.19.2 reboxetine Drug Overview
4.19.3 reboxetine Mechanism of Action
4.19.4 reboxetine Licensing/Collaboration Companies
4.19.5 reboxetine Clinical Trials
5. LATEST NARCOLEPSY PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
